{"id":3744,"date":"2026-02-23T15:15:28","date_gmt":"2026-02-23T15:15:28","guid":{"rendered":"https:\/\/tradertideinsights.com\/?p=3744"},"modified":"2026-02-23T15:15:28","modified_gmt":"2026-02-23T15:15:28","slug":"almirall-profit-quadruples-in-2025-as-dermatology-fuels-growth-push","status":"publish","type":"post","link":"https:\/\/tradertideinsights.com\/?p=3744","title":{"rendered":"Almirall profit quadruples in 2025 as dermatology fuels growth push"},"content":{"rendered":"
<\/div>\n

Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of \u20ac46.2 million<\/a>, which was 357% more than its 2024 profit of \u20ac10.1 million. <\/p>\n

The Barcelona-based pharmaceutical company was able to exceed the significant \u20ac1 billion sales threshold thanks to a 12.5% increase in revenue to \u20ac1.1145 billion.<\/p>\n

Following a more muted 2024, the corporation has regained pace, according to the figures, which were made public on Monday. <\/p>\n

Due to increased sales and better operational efficiency, operating profit (EBITDA) increased 20.9% to \u20ac232.9 million.<\/p>\n

Net revenues increased 12.4% from the prior year to \u20ac1.1081 billion. <\/p>\n

Strong performance in biologic pharmaceuticals and ongoing demand in Europe, the group’s primary market, were major factors in the rise.<\/p>\n

The 2025 numbers indicate to investors and industry watchers that Almirall’s strategic concentration on specialised dermatology, especially biologic therapies, is starting to result in steady earnings growth.<\/p>\n

The sales mix is dominated by Europe<\/h2>\n

Geographically, Almirall’s business is still centred in Europe. In 2025, the region brought in \u20ac1.0059 billion, up 14.9% from 2024. <\/p>\n

This indicates that 90.8% of the company’s worldwide sales came from Europe.<\/p>\n

The US, on the other hand, only contributed \u20ac45.2 million, a decrease of 18.4% from the previous year, underscoring Almirall’s very small presence in the biggest pharmaceutical market in the world. <\/p>\n

Other regions had a 3.4% increase in sales to \u20ac57 million.<\/p>\n

Strength and risk are shown by this regional concentration. Almirall is still largely dependent on a single region, even though Europe provides steady growth and a familiar regulatory framework.<\/p>\n

The difficulties mid-sized European pharmaceutical companies encounter when competing in fiercely competitive and price-sensitive international markets are exemplified by their poor US performance in 2025.<\/p>\n

At the centre of strategy is dermatology.<\/h2>\n

Almirall’s growth engine is still dermatology. In 2025, the company’s dermatological division brought in \u20ac669.4 million, up 22.1% from the year before and accounting for 60.4% of total net sales.<\/p>\n

Two important items were particularly noteworthy:<\/p>\n

\u2022 The psoriasis therapy Illumetri brought in \u20ac234.4 million, a 12.3% increase over the previous year.<\/p>\n

\u2022 Ebglyss, which is prescribed for atopic dermatitis, generated \u20ac110.8 million, which is almost four times as much as it did in 2024.<\/p>\n

Strong market uptake is indicated by the dramatic increase in Ebglyss sales, which places the medication as a possible pillar of future growth. <\/p>\n

These biologic treatments, along with Illumetri, show Almirall’s preference for more expensive, specialised medications over commoditised generics.<\/p>\n

In 2025, the firm spent \u20ac138.1 million, or 12.5% of net sales, on research and development. <\/p>\n

Its goal to maintain its dermatology pipeline and grow in advanced medicines is in keeping with this level of R&D activity.<\/p>\n

Aiming for double digits by 2030<\/h2>\n

Almirall set high medium-term goals and stated in its presentation to the market that the company had achieved its 2025 projection. <\/p>\n

The company wants to increase its EBITDA margin to about 25% by 2028 and anticipates double-digit net sales growth every year through 2030.<\/p>\n

Almirall particularly projects revenue growth of 9% to 12% in 2026. <\/p>\n

It forecasts EBITDA between \u20ac270 million and \u20ac290 million, indicating that operating leverage will persist as fresh products develop.<\/p>\n

Additionally, the group expressed a readiness to actively explore early-stage licensing agreements in potential advanced therapeutics and to pursue “opportunistic acquisitions” of assets that have already been commercialised. <\/p>\n

This two-pronged approach, which combines judicious dealmaking with organic development, could hasten expansion without going over budget.<\/p>\n

Governance and the balance sheet<\/h2>\n

Almirall’s debt was \u20ac283.7 million at the end of 2025, \u20ac63.7 million less than it was in 2024. <\/p>\n

The net debt to EBITDA ratio is 0x, which allows it flexibility in future licensing or purchase deals.<\/p>\n

The Gallardo family controlled the business, which also released its yearly compensation report. In 2025, Chairman Carlos Gallardo’s pay increased by 4.57% to \u20ac1.78 million.<\/p>\n

Implications for investors<\/h2>\n

The performance of Almirall in 2025 shows that the business is moving from recovery to expansion. <\/p>\n

Its speciality-focused approach appears to be working, as evidenced by dermatology’s robust performance, solid double-digit sales growth, and profit quadrupling.<\/p>\n

Its strong reliance on Europe and diminishing revenues in the US, however, remain fundamental issues. Future expansion is likely to depend on the continued success of the flagship biologics, R&D productivity, and prudent capital deployment.<\/p>\n

In addition to being a successful year, 2025 might be seen as the turning point in a longer-term shift if Almirall can sustain double-digit sales growth while increasing margins in the direction of its 2028 goal.<\/p>\n<\/p>\n

The post Almirall profit quadruples in 2025 as dermatology fuels growth push<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of \u20ac46.2 million, which was 357% more than its 2024 profit of \u20ac10.1 million. The Barcelona-based pharmaceutical company was able to exceed the significant \u20ac1 billion sales threshold thanks to a 12.5% increase in revenue to \u20ac1.1145 billion.Following a more muted 2024,…<\/p>\n","protected":false},"author":1,"featured_media":3745,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3744"}],"version-history":[{"count":0,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3744\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/media\/3745"}],"wp:attachment":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}